{"id":61646,"date":"2025-07-28T10:04:16","date_gmt":"2025-07-28T08:04:16","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\/"},"modified":"2025-07-28T10:04:16","modified_gmt":"2025-07-28T08:04:16","slug":"biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\/","title":{"rendered":"Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website"},"content":{"rendered":"
\n

BEIJING–(BUSINESS WIRE)–#AntibodyDiscovery<\/a>–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a comprehensive upgrade to its preclinical business division. The upgrade features an expanded portfolio of genetically engineered animal models\u2014including target-humanized, immune-humanized, transgenic, and immunodeficient mice\u2014alongside a full suite of preclinical services such as efficacy studies, PK\/PD analysis, biomarker evaluation, and non-GLP toxicology testing. In parallel, the company also launched its new official website (https:\/\/biocytogen.com<\/a>), featuring an intuitive structure, enriched content, and an optimized multilingual user experience to serve global clients and partners better.<\/p>\n

<\/a>
<\/a><\/p>\n

\nExtensive Model Portfolio with Over 1,100 Target-Humanized Mouse Models<\/b><\/p>\n

\nIn 2021, Biocytogen launched the \u201cBioMice\u201d sub-brand to advance its portfolio of genetically engineered mouse models. Leveraging its proprietary gene-editing platform, the company has developed more than 1,100 target-humanized mice. These models are generated using precise in situ gene replacement technology, which substitutes mouse genes with human sequences while preserving endogenous gene regulation. This approach enables a more accurate simulation of human physiological and pathological conditions, establishing BioMice as the gold-standard platform for evaluating the efficacy and safety of various therapeutic modalities, including antibody drugs, cell therapies, bispecific\/multispecific antibodies, ADCs, and oligonucleotide-based treatments.<\/p>\n

\nThe company has established high-value disease models for oncology, autoimmune, metabolic, and neurological disorders, including CD3 (TCEs), HER2 (TAAs), TL1A (IBD), TSLP (AD), GLP1R (muscle gain\/weight loss), and TFR1 (BBB delivery). These models are widely used for target validation, mechanistic studies, and preclinical evaluations. To date, safety data generated from these models have supported 15 IND approvals by China\u2019s NMPA and 5 IND approvals by the U.S. FDA (including 4 dual submissions). Biocytogen also offers immune-humanized mouse models (e.g., huPBMC-B-NDG, huHSC-B-NDG, huHSC-B-NDG hIL15, and huPBMC-B-NDG MHC I\/II DKO plus), transgenic mice, and immunodeficient strains to support evaluations of immuno-oncology agents, T\/NK cell therapies, and immunostimulatory drugs, building a comprehensive and multi-dimensional model portfolio.<\/p>\n

\nGlobal Animal Supply Network Supporting Efficient Preclinical Research<\/b><\/p>\n

\nBiocytogen operates three AAALAC-accredited animal facilities in Haimen (Jiangsu), Daxing (Beijing), and Boston (USA), covering a total area of 55,000 m\u00b2 and offering an annual supply capacity of over 800,000 laboratory animals. With a robust quality control system and standardized microbial monitoring, Biocytogen has established an international distribution network spanning Asia, Europe, and North America. The company\u2019s mouse models have been successfully delivered to clients in over 20 countries and regions, providing reliable model support for global drug development efforts.<\/p>\n

\nIntegrated Preclinical Services to Accelerate IND Filing and Clinical Translation<\/b><\/p>\n

\nLeveraging its proprietary animal models, Biocytogen provides one-stop, non-GLP preclinical products and services, including in vivo<\/i> efficacy testing, PK\/PD analysis, biomarker assessment, and early toxicology studies. With a vast collection of CDX and PDX tumor models and customizable study designs, Biocytogen serves over 20 therapeutic areas\u2014including solid tumors, hematologic malignancies, autoimmune diseases, metabolic disorders, and neurodegenerative diseases\u2014and supports a variety of drug modalities such as antibodies, small molecules, ADCs, bispecifics, cell therapies, nucleic acids, and vaccines. As of now, Biocytogen has completed more than 5,300 drug evaluation studies for nearly 900 pharmaceutical and academic institutions worldwide.<\/p>\n

\nOver One Million Fully Human Antibodies Empowering Antibody Drug Discovery<\/b><\/p>\n

\nBeyond preclinical services, Biocytogen also leads in antibody discovery through its proprietary RenMice\u00ae<\/sup> platforms\u2014including RenMab\u2122 (fully human antibody), RenLite\u00ae<\/sup> (common light chain), RenNano\u00ae<\/sup> (VHH antibody), RenTCR\u2122 (fully human TCR), and RenTCR-mimic\u2122 (fully human TCR-mimic antibody). The company has built a library of over one million fully human antibody sequences against more than 1,000 potential therapeutic targets, with diverse structures and functional profiles. As of December 31, 2024, Biocytogen has signed approximately 200 drug co-development, licensing, or transfer agreements, including over 50 target-based RenMice\u00ae<\/sup> platform collaborations with multinational pharmaceutical companies. Multiple clinical-stage antibody candidates have also been successfully out-licensed to global partners. Biocytogen\u2019s integrated capabilities in antibody discovery, screening, and engineering are accelerating the transition from target validation to clinical candidate selection, empowering global biopharmaceutical innovation.<\/p>\n

\nNew Official Website Launched to Serve Global Clients<\/b><\/p>\n

\nTo enhance global service capabilities, Biocytogen has officially launched its new website: https:\/\/biocytogen.com<\/a>.<\/span> Designed for a clean and intuitive user experience, the new site features streamlined architecture, upgraded content organization, improved search functionality, and multilingual support in Chinese, English, Japanese, and Korean. Structured around its two main business divisions\u2014BioMice\u00ae<\/sup> for preclinical products and services and RenBiologics\u2122 for antibody discovery and collaboration\u2014the site offers a comprehensive overview of Biocytogen\u2019s model products, antibody assets, project portfolios, and service capabilities. It provides an efficient and direct information portal for global partners and supports the company\u2019s ongoing internationalization strategy.<\/p>\n

\nAbout Biocytogen<\/b><\/p>\n

\nBiocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice\u00ae<\/sup> (RenMab\u2122\/ RenLite\u00ae<\/sup>\/ RenNano\u00ae<\/sup>\/ RenTCR-mimic\u2122) platforms for fully human monoclonal\/bispecific\/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics\u2122, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development\/out-licensing\/transfer agreements and over 50 target-nominated RenMice\u00ae<\/sup> licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice\u2122, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https:\/\/biocytogen.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nBiocytogen Contacts<\/b>
Preclinical Products and Services: info@biocytogen.com<\/a>
Antibody assets and platforms: BD-Licensing@biocytogen.com<\/a>
Media: pr@bbctg.com.cn<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BEIJING–(BUSINESS WIRE)–#AntibodyDiscovery–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a comprehensive upgrade to its preclinical business division. The upgrade features an expanded portfolio of genetically engineered animal models\u2014including target-humanized, immune-humanized, transgenic, and immunodeficient mice\u2014alongside a full … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61646","6":"format-standard","7":"category-industry"},"yoast_head":"\nBiocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BEIJING–(BUSINESS WIRE)–#AntibodyDiscovery–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a comprehensive upgrade to its preclinical business division. The upgrade features an expanded portfolio of genetically engineered animal models\u2014including target-humanized, immune-humanized, transgenic, and immunodeficient mice\u2014alongside a full ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-28T08:04:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250728835434\/en\/2535082\/22\/Logo_of_Biocytogen_on_Business_wire.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website\",\"datePublished\":\"2025-07-28T08:04:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\\\/\"},\"wordCount\":975,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250728835434\\\/en\\\/2535082\\\/22\\\/Logo_of_Biocytogen_on_Business_wire.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\\\/\",\"name\":\"Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250728835434\\\/en\\\/2535082\\\/22\\\/Logo_of_Biocytogen_on_Business_wire.jpg\",\"datePublished\":\"2025-07-28T08:04:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250728835434\\\/en\\\/2535082\\\/22\\\/Logo_of_Biocytogen_on_Business_wire.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250728835434\\\/en\\\/2535082\\\/22\\\/Logo_of_Biocytogen_on_Business_wire.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\/","og_locale":"en_US","og_type":"article","og_title":"Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website - Pharma Trend","og_description":"BEIJING–(BUSINESS WIRE)–#AntibodyDiscovery–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a comprehensive upgrade to its preclinical business division. The upgrade features an expanded portfolio of genetically engineered animal models\u2014including target-humanized, immune-humanized, transgenic, and immunodeficient mice\u2014alongside a full ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\/","og_site_name":"Pharma Trend","article_published_time":"2025-07-28T08:04:16+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250728835434\/en\/2535082\/22\/Logo_of_Biocytogen_on_Business_wire.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website","datePublished":"2025-07-28T08:04:16+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\/"},"wordCount":975,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250728835434\/en\/2535082\/22\/Logo_of_Biocytogen_on_Business_wire.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\/","url":"https:\/\/pharma-trend.com\/en\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\/","name":"Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250728835434\/en\/2535082\/22\/Logo_of_Biocytogen_on_Business_wire.jpg","datePublished":"2025-07-28T08:04:16+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250728835434\/en\/2535082\/22\/Logo_of_Biocytogen_on_Business_wire.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250728835434\/en\/2535082\/22\/Logo_of_Biocytogen_on_Business_wire.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/biocytogen-upgrades-preclinical-service-platform-and-launches-revamped-global-website\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61646"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61646\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61646"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61646"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}